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Vaes RD, van den Berk L, Boonen B, van Dijk DP, Olde
Damink SW, Rensen SS. A novel human cell culture model to study
visceral smooth muscle phenotypic modulation in health and disease.
Am J Physiol Cell Physiol 315: C598–C607, 2018. First published
July 25, 2018; doi:10.1152/ajpcell.00167.2017.—Adaptation of the
smooth muscle cell (SMC) phenotype is essential for homeostasis and
is often involved in pathologies of visceral organs (e.g., uterus,
bladder, gastrointestinal tract). In vitro studies of the behavior of
visceral SMCs under (patho)-physiological conditions are hampered
by a spontaneous, uncontrolled phenotypic modulation of visceral
SMCs under regular tissue culture conditions. We aimed to develop a
new visceral SMC culture model that allows controlled phenotypic
modulation. Human uterine SMCs [ULTR and telomerase-immortal-
ized human myometrial cells (hTERT-HM)] were grown to conflu-
ency and kept for up to 6 days on regular tissue culture surfaces or
basement membrane (BM) matrix-coated surfaces in the presence of
0–10% serum. mRNA and protein expression and localization of
SMC-specific phenotype markers and their transcriptional regulators
were investigated by quantitative PCR, Western blotting, and immu-
nofluorescence. Maintaining visceral SMCs confluent for 6 days
increased -smooth muscle actin (1.9-fold) and smooth muscle pro-
tein 22- (3.1-fold), whereas smooth muscle myosin heavy chain was
only slightly upregulated (1.3-fold). Culturing on a BM matrix-coated
surface further increased these proteins and also markedly promoted
mRNA expression of -smooth muscle actin (15.0-fold), smoothelin
(3.5-fold), h-caldesmon (5.2-fold), serum response factor (7.6-fold),
and myocardin (8.1-fold). Whereas additional serum deprivation only
minimally affected contractile markers, platelet-derived growth fac-
tor-BB and transforming growth factor 1 consistently reduced versus
increased their expression. In conclusion, we present a simple and
reproducible visceral SMC culture system that allows controlled
phenotypic modulation toward both the synthetic and the contractile
phenotype. This may greatly facilitate the identification of factors that
drive visceral SMC phenotypic changes in health and disease.
basal membrane matrix; differentiation; phenotypic modulation; vis-
ceral smooth muscle
INTRODUCTION
The walls of many visceral organs are surrounded by well-
developed smooth muscle layers that enable endured constric-
tion or dilation, resulting in transport or storage of fluids. The
smooth muscle cells (SMCs) within these layers possess the
unique ability to change their phenotype from a so-called
contractile state toward a synthetic state. Whereas contractile
SMCs are characterized by an elongated spindle-shaped mor-
phology and high expression of specific contractile marker
proteins (31), synthetic SMCs show a decreased expression of
these contractile markers and an increased proliferation rate,
high migration rate, and pronounced synthesis of extracellular
matrix proteins (31).
SMC phenotypic plasticity is essential for adaptation of
visceral organs to changes in local environmental conditions in
health. For example, during pregnancy, uterine SMC hypertro-
phy and collagen synthesis are induced by ovarian hormones to
cope with the stretch induced by the growing fetus and to
maintain a quiescent contractile state until delivery (2, 15, 32).
However, SMC phenotypic plasticity can also contribute to
disease. An example is inflammatory bowel disease, where
increased TNF- and IL-1 levels reduce intestinal SMC
contractility, contributing to intestinal motility problems (22–
24). SMC hypertrophy and reduced smooth muscle contractil-
ity also underlie the significant increase in bladder mass during
partial bladder outlet obstruction secondary to prostatic hyper-
plasia (3, 5, 42).
Given the importance of visceral SMC phenotypic plasticity
for the pathogenesis of various disorders as well as normal
physiological phenomena, it is pivotal to gain more mechanis-
tic insight into the molecular processes involved and the
relevant environmental cues. To this end, a visceral SMC
culture system in which the SMC phenotype can be modulated
in a controlled way is a prerequisite. Unfortunately, SMCs
modulate uncontrollably toward a synthetic phenotype under
standard cell culture conditions that lack the physiological
microenvironment that normally keeps the cells in a contractile
phenotype (6). In particular, a highly structured basal mem-
brane (BM) matrix has been shown to be crucial for maintain-
ing the contractile SMC phenotype (36). Additional elements
of the cellular environment, including cell-cell interactions
(18), humoral factors (e.g., growth factors, cytokines) (18), and
mechanical forces, further regulate the SMC phenotype.
We here present the first visceral SMC culture system in
which SMCs can be kept in either a highly contractile state or
modulated toward the synthetic phenotype in a controlled way,
developed by careful optimization of the growth surface, serum
concentration, and cell-cell interaction. For the optimization of
this culture model, we used well-characterized immortalized
human uterine SMC lines that retain in vivo SMC character-
istics, such as the expression of contractile and myometrial
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SMC markers (7, 28). This novel culture model can be used to
further elucidate the molecular mechanisms driving SMC phe-
notypic switching and greatly facilitates the study of visceral
SMC phenotypic modulation in health and disease.
MATERIALS AND METHODS
Cell culture conditions. Human uterine SMCs (ULTR cells) (28)
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(GIBCO, cat. no. 42430) supplemented with 4 mM L-Glutamine, 10%
(vol/vol) fetal bovine serum (FBS) (Greiner Bio-one, cat. no. 758093),
and antibiotics (100 U/ml penicillin and 100 g/ml streptomycin;
GIBCO). Human myometrial SMCs immortalized with human telom-
erase reverse transcriptase (hTERT-HM) were a gift from Dr. Jennifer
Condon (7). These cells were maintained in DMEM/F12 (GIBCO, cat.
no. 31331) supplemented with 10% FBS, 10 mM HEPES (GIBCO,
cat. no. 15630), and antibiotics (100 U/ml penicillin and 100 g/ml
streptomycin). All experiments were performed within 8 passages,
and both cell lines were maintained at 37°C, 5% CO2 in a humidified
incubator.
For experiments, SMCs were plated at a density of 1  104
cells/cm2 on either standard tissue culture (TC)-treated (Eppendorf) or
BM matrix-coated (Geltrex Reduced Growth Factor Basement Mem-
brane Matrix, GIBCO, cat no. A14132) surfaces. To obtain BM-
coated plates, tissue culture-treated multiwell polystyrene plates (Ep-
pendorf) were coated with 100 l/cm2 ice-cold Geltrex (1:50 in
DMEM without supplements) and incubated for 2 h at 37°C before
plating cells. Subsequently, when cells reached 90% confluency
(after 48 h), regular culture medium used for maintaining the cells was
replaced by advanced DMEM/F-12 (GIBCO, cat. no. 12634) that
allows culturing cells with reduced serum supplementation due to the
addition of specific components, including ethanolamine, glutathione,
ascorbic acid, insulin, transferrin, and AlbuMAX lipid-rich bovine
serum albumin. Advanced DMEM/F-12 medium was supplemented
with different serum concentrations (10%, 2%, or 0% FBS), 1%
(vol/vol) GlutaMAX (GIBCO, cat. no. 35050), and antibiotics (50
U/ml penicillin and 50 g/ml streptomycin; GIBCO). In indicated
experiments, SMCs were treated with either PDGF-BB (30 ng/ml;
PeproTech, cat. co. 100–14B) or transforming growth factor 1
(TGF-1) (5 ng/ml; PeproTech, cat. no. 100–21) to induce pheno-
typic modulation. Medium was refreshed every 3 days.
Quantitative real-time PCR. Total RNA was isolated using TRI
Reagent (Sigma, St. Louis, MO) according to the manufacturer’s
protocol. RNA yield was measured with a DeNovix DS-11 spectro-
photometer. A total of 750 ng RNA were reversed transcribed to
cDNA using the SensiFast cDNA Synthesis Kit according to the
manufacturer’s instructions (Bioline GmbH, Germany).
To quantify mRNA expression levels of SMC phenotype markers,
quantitative real-time PCR (qRT-PCR) analysis was performed on the
LightCycler480 (Roche) using a three-step PCR program followed by
melting curve analysis. cDNA was amplified with the SensiMix
SYBR Hi-Rox Kit (Bioline, cat. no. QT605-05). Specific primer pairs
for each gene were ordered from Sigma and are listed in Table 1.
Relative gene expression levels were derived from the LinRegPCR
(version 2016.1) method (33) and normalized to the geometric aver-
age of two reference genes, cyclophylin A (CYPA) and -2-micro-
globulin (B2M).
Western blotting. Cells were harvested with lysis buffer containing
10 mM Tris, 100 mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton
X-100, 10% glycerol, 0.1% (wt/vol) SDS, and 0.5% (vol/vol) sodium
deoxycholate supplemented with protease inhibitor cocktail tablets
(Roche, Mannheim, Germany). Whole cell lysates were incubated on
ice for 30 min and subsequently centrifuged at 16,000 g for 30 min at
4°C. Supernatant was transferred to a new tube, and total soluble
protein concentrations were determined using the Pierce BCA Protein
Assay Kit (Thermo Fisher, Rockford, IL). Laemmli sample buffer
[4; 250 mM Tris·HCl, pH 6.8, 8% (wt/vol) SDS, 40% (vol/vol)
glycerol, 355 mM 2-Mercaptoethanol, and 0.02% (wt/vol) bromophe-
nol blue] was added to the lysate, followed by heating the samples for
5 min at 95°C. Equal amounts of protein (10 g) were loaded per lane
on a 4%–15% Criterion TGX Stain-Free precast Gel (Bio-Rad).
Following electrophoretic separation, the proteins were transferred
onto a Transblot Turbo polyvinylidene difluoride transfer membrane
(Bio-Rad) by electro-blotting on the Trans-Blot Turbo Blotting Sys-
tem (Bio-Rad). After blocking with 5% (wt/vol) BSA (Lampire
Biological Laboratories, cat. no. 7500804), membranes were incu-
bated overnight at 4°C with specific monoclonal primary antibodies
directed against anti-smooth muscle myosin heavy chain (anti-SM-
MHC) (1:1,000, Clone BT-562, Alfa Aesar, cat. no. J64817AMJ),
anti--smooth muscle actin (anti--SMA) (1:1,000, Clone 1A4,
DAKO, cat. no. M0851), and anti-smooth muscle protein 22- (anti-
SM22) (1:1,000) (the mouse anti-SM22 hybridoma cell line, clone
3E11, was a kind gift from Dr. A. Chiavegato, University of Padua,
Italy). After washing with Tris-buffered saline-Tween 20 (0.01%), the
blots were probed for 1 h with an appropriate peroxidase-conjugated
secondary antibody (Vector Laboratories), and signals were visualized
using SuperSignal West Pico chemiluminescent substrate (Thermo
Scientific) according to the manufacturer’s instructions. Images were
obtained with a molecular imager (Amersham Imager 600, GE
Healthcare Life Sciences), and total band intensity was quantified with
ImageQuant TL software (v8.1.0.0, GE Healthcare Life Sciences).
Immunofluorescence. For double immunofluorescence staining,
uterine SMCs were cultured on 18-mm glass coverslips (Thermo
Scientific). Cells were fixed for 5 min in 50% (vol/vol) methanol/50%
(vol/vol) acetone at 20°C. Subsequently, cells were rinsed in Dul-
becco’s PBS (GIBCO, Life Technologies), followed by a 60-min
incubation with mouse monoclonal IgG2a antibody recognizing anti-
-SMA (1:200, Clone 1A4, DAKO) and mouse monoclonal IgG1
antibody recognizing SM22 (1:150, Clone 3E11). Alexa Fluor 488-
conjugated goat anti-mouse IgG1 (Invitrogen, cat. no. A-21121) and
Alexa Fluor 594-conjugated goat anti-mouse IgG2a (Invitrogen, cat.
no. A-21135) were used as secondary antibodies. Nuclei were coun-
terstained by 4=,6=-diamidino-2-phenylindole. Coverslips were
mounted in fluorescent mounting medium (DAKO). Digital images
were taken using a Leica TCS SP8 X automated inverted confocal
microscope equipped with an HC PL APO CS2 63x/1.40 oil objective
and processed using ImageJ (version 1.51h).
Statistical analysis. Data are obtained from two or three indepen-
dent experiments, and results are expressed as mean 	 SE. Raw data
was entered in IBM SPSS 24 for Microsoft Windows, and statistical
analyses were performed using the nonparametric Mann-Whitney
U-test to compare differences between two groups. In case of more
than two groups, the nonparametric Kruskal-Wallis test was applied,
followed by Dunn’s post hoc testing with Bonferroni correction. A P
value of P 
 0.05 was considered statistically significant.
Table 1. Quantitative RT-PCR primers
Gene Forward Primer (5=¡3=) Reverse Primer (5=¡3=)
CYPA CTCGAATAAGTTTGACTTGTGTTT CTAGGCATGGGAGGGAACA
B2M TCCATCCGACATTGAAGTTG CGGCAGGCATACTCATCTT
ACTA2 CCGGGACTAAGACGGGAATC TTGTCACACACCAAGGCAGT
ACTG2 CGCCCTCGCCACCAG CCTTGGGATTTAGGGGAGCC
TAGLN AATTGATGGAAACCACCGGG GGGGAAAGCTCCTTGGAAGT
SMTN ACCATCGAGATCAAGGACGG CCAGTGTCAGTTCTGCCCTC
CALD1 GCTGTCCTAAAGAAACAGGGAG GGCTTGTCTTCTTGGAGCTT
MYH11 CATCTACGCCATCGCAGACA CAGACTCGCCTGTGCATAGAA
MYOCD GGGTCTGAGCATTCCTTGCT CTGGACGTTTCAGTGGTGGT
SRF TTGCTGAGTGAAGGGGCCTA AGTTTTCGGGTGGCAAAGGT
ACTA2, -smooth muscle actin; ACTG2, -smooth muscle actin; B2M,
-2-microglobulin; CALD1, caldesmon 1 (primers specific for heavy caldes-
mon transcript); CYPA, cyclophilin A; MYH11, myosin heavy chain 11;
MYOCD, myocardin; SMTN, smoothelin; SRF, serum response factor; TAGLN,
smooth muscle protein 22-.
C599CONTROLLED PHENOTYPIC MODULATION OF HUMAN VISCERAL SMCs
AJP-Cell Physiol • doi:10.1152/ajpcell.00167.2017 • www.ajpcell.org
Downloaded from journals.physiology.org/journal/ajpcell at Universiteit Maastricht (137.120.156.250) on October 29, 2020.
RESULTS
Effect of prolonged cell-cell contact on SMC-specific con-
tractile markers. Reduced cell-cell contact as a consequence of
culturing SMCs at a low density has previously been shown to
result in a decreased expression of contractile marker proteins
(18). At confluence, vascular SMCs lose their proliferative
capacity and concurrently increase their expression of a panel
of SMC-specific contractile proteins like -SMA, SM22, and
SM-MHC. To investigate whether visceral SMCs exhibit a
similar cellular behavior, we cultured ULTR cells toward a
confluent state and maintained them for 3 or 6 days in the
presence of 10% FBS before analyzing contractile marker
expression. These immortalized cells have previously been
shown to acquire characteristics of the synthetic SMC pheno-
type when cultured toward a subconfluent state, including a
high proliferation rate, decreased cell size, and irregular dis-
tribution of -actin filaments (28). Culturing ULTR SMCs for
3 days in a confluent state resulted in slightly increased
SM-MHC and SM22 protein levels, but these differences
were not significant (Fig. 1A). However, contractile protein
levels continued to increase; after 6 days, SM22 protein
levels were significantly increased by 3.1-fold (P  0.01), and
-SMA protein levels tended to be significantly increased
(1.9-fold, P  0.09). These protein data indicate that increasing
cell-cell contact only minimally promotes the contractile phe-
notype in visceral SMCs. However, mRNA expression of
many contractile marker genes was significantly increased after
6 days (Fig. 1B): ACTA2 (5.3-fold, P 
 0.001), ACTG2
(1.3-fold, P 
 0.001), CALD1 (2.2-fold, P  0.03), and
MYH11 (2.2-fold, P  0.04). This suggests that increased
cell-cell contact initiates transcriptional upregulation of con-
tractile genes, although this was not sufficient to induce dif-
ferences at the protein level. Nevertheless, transcription of
serum response factor (SRF) and myocardin (MYOCD), genes
important for transcriptional regulation of the contractile phe-
notype markers, was not induced by prolonged confluency
(Fig. 1C).
Basement membrane components promote the visceral SMC
contractile phenotype. Since the interaction of cells with the
extracellular microenvironment is known to influence vascular
SMC differentiation, migration, proliferation, and survival
(30), we next investigated whether the addition of basal mem-
brane matrix (BM) components could further stimulate the
expression of contractile proteins in visceral SMCs. In com-
parison with cells grown on TC-coated surfaces (Fig. 1), SMCs
cultured on a BM-coated surface showed a higher increase of
ACTA2 gene expression after 6 days of culturing at confluency
(TC: 2.9-fold, P 
 0.001 vs. BM: 8.2-fold, P  0.002) (Fig.
2A). More importantly, cells grown on BM markedly upregu-
lated their expression of the more advanced contractile pheno-
type markers (ACTG2, 15.0-fold, P  0.002; TAGLN, 3.2-fold,
P  0.7; SMTN, 3.5-fold, P  0.002; CALD1, 5.2-fold, P 
0.004) (Fig. 2A) compared with the SMCs grown on TC-coated
surfaces (Fig. 1B). These inductions were also observed at the
protein level, where expression of -SMA was increased by
3.9-fold (P 
 0.001) and expression of SM22 by 4.8-fold
(P 
 0.001) (Fig. 2B). In addition, SM-MHC protein levels
were significantly enhanced in cells grown on BM matrix
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Fig. 1. Expression of smooth muscle cell (SMC)-specific contractile markers in confluent visceral SMCs. Visceral SMCs (ULTR cells) were cultured on a tissue
culture (TC)-coated surface in medium containing 10% FBS. A: protein expression of smooth muscle myosin heavy chain (SM-MHC), -smooth muscle actin
(-SMA), and smooth muscle protein 22- (SM22) was determined by Western blot analysis. All samples from each independent experiment (SM-MHC,
n  6; -SMA and SM22, n  9) were derived at the same time and processed in parallel. B and C: mRNA expression levels of contractile (ACTA2, ACTG2,
TAGLN, SMTN, CALD1, and MYH11) (B) and transcriptional regulatory (SRF, MYOCD) (C) genes were determined and are expressed relative to expression
levels at day 0. Data were normalized to CYPA and B2M reference genes. Results from each time point were obtained from two (CALD1 and MYH11; n  6)
or three (ACTA2, ACTG2, TAGLN, SMTN, SRF, and MYOCD; n  9) independent experiments and are presented as mean 	 SE (*P 
 0.05 compared with D0,
Kruskal-Wallis test followed by Dunn’s post hoc testing with Bonferroni correction). ACTA2, -smooth muscle actin; ACTG2, -smooth muscle actin; B2M,
-2-microglobulin; CALD1, caldesmon; CYPA, cyclophilin A; MYH11, smooth muscle myosin heavy chain; MYOCD, myocardin; SMTN, smoothelin; SRF,
serum response factor; TAGLN, smooth muscle protein 22-.
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(2.2-fold, P  0.002). Moreover, mRNA expression of tran-
scriptional regulators of the contractile phenotype was highly
upregulated in SMCs cultured on BM matrix (SRF: 7.6-fold,
P  0.002; MYOCD: 8.1-fold, P  0.002) (Fig. 2C).
Effect of serum concentrations on the phenotype of SMCs
grown on BM matrix. Growth factors present in FBS are
known to stimulate cell proliferation, migration, and matrix
protein synthesis, which are all characteristics of the synthetic
SMC phenotype. We therefore investigated whether reducing
serum concentrations could further promote the contractile
phenotype of visceral SMCs grown on BM matrix for 6 days.
In comparison with the 10% FBS condition, only -SMA
protein levels were slightly increased (1.3-fold, Fig. 3A) when
cells were cultured in 2% or 0% FBS, although these increases
were not significant. However, SM-MHC and SM22 protein
concentrations were similar when cells were grown in 10%
versus 2% FBS (Fig. 3A), and complete serum deprivation
even caused significantly decreased SM-MHC (0.7-fold, P 
0.03) and SM22 protein expression (0.4-fold, P  0.005)
(Fig. 3A). Of note, complete serum deprivation seemed to
reduce cell viability, as indicated by cell morphology and the
appearance of floating cells (data not shown). At the mRNA
level, reducing serum concentrations did not increase expres-
sion of contractile phenotype markers in comparison with the
10% FBS condition (Fig. 3B), except for CALD1, which was
slightly upregulated. This suggests that the known inhibitory
effect of the growth factors on the SMC contractile phenotype
is blunted when cells are grown on a BM matrix.
Visceral SMCs undergo morphological and structural
changes within an optimized SMC culture environment. The
results presented above indicate that by optimizing culture
conditions, visceral SMCs maintain a relatively contractile
phenotype characterized by high contractile marker protein
expression. Consistent with this, the SMCs cultured at these
optimized conditions underwent the typical morphological
changes that SMCs undergo during acquisition of a contractile
phenotype. Whereas a heterogeneous population of rhomboid-
and elongated spindle-shaped cells was present at day 0, cells
cultured on basement membrane matrix proteins acquired the
typical contractile phenotype-associated elongated spindle-
shaped morphology upon 6 days of culturing (Fig. 4A). These
morphological changes were accompanied by pronounced re-
arrangements of the contractile apparatus; -SMA filaments in
synthetic rhomboid SMCs ran crisscross through the cytoplasm
(Fig. 4B, a–c), whereas they reorganized to run parallel to the
long axis in elongated spindle-shaped SMCs (Fig. 4B, d–f).
Moreover, SM22 was abundantly present along the actin
filaments in contractile SMCs (Fig. 4B, d–f) compared with
synthetic SMCs, in which SM22 was only marginally ex-
pressed and appeared to show less colocalization with -SMA
filaments (Fig. 4B, a–c).
The contractile phenotype of visceral SMCs grown on BM
can be modulated in a controlled way. To further show the
potential of this culture system for modeling disease states
characterized by SMC phenotypic changes, we stimulated the
cells with factors known to influence the vascular SMC phe-
notype (PDGF-BB and TGF-1). In vascular SMCs,
PDGF-BB has been shown to suppress the contractile pheno-
type, whereas TGF-1 stimulates it (8, 13). PDGF-BB and
TGF-1 stimulation greatly influenced both protein and gene
expression levels of contractile SMC markers of visceral SMCs
cultured for 6 days on a BM-coated growth surface with 2%
FBS. SMCs incubated for 48 h with PDGF-BB showed re-
duced protein levels of -SMA (0.5-fold, P  0.048), and
SM22 (0.6-fold, P  0.4) tended to be decreased as well (Fig.
5A). Conversely, stimulation with TGF-1 further increased
protein expression of both -SMA (2.3-fold, P  0.048) and
SM22 (1.9-fold, P  0.04, Fig. 5A) in cells that already had
a contractile phenotype as a result of culturing on BM matrix.
Although protein levels of -SMA and SM22 were altered
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Fig. 2. Culturing visceral smooth muscle cells
(SMCs) on a basement membrane (BM) ma-
trix-coated surface promotes a contractile
phenotype. Visceral SMCs (ULTR) were
seeded on a BM-coated growth surface in
medium containing 10% FBS. A and B:
mRNA expression levels of contractile
(ACTA2, ACTG2, TAGLN, SMTN, CALD1,
and MYH11) (A) and transcriptional regula-
tory (SRF, MYOCD) (B) genes were deter-
mined and are expressed as relative expres-
sion levels with day 0 samples set at 1. Data
were normalized to CYPA and B2M reference
genes. C: protein expression levels of smooth
muscle myosin heavy chain (SM-MHC),
-smooth muscle actin (-SMA), and smooth
muscle protein 22- (SM22) (C) were de-
termined by Western blot analysis. All sam-
ples from each independent experiment were
derived at the same time and processed in
parallel (SM-MHC, n  6; -SMA and
SM22, n  9). Results are presented as
mean 	 SE (Mann-Whitney U-test, *P 

0.05). ACTA2, -smooth muscle actin;
ACTG2, -smooth muscle actin; B2M, -2-
microglobulin; CALD1, caldesmon; CYPA,
cyclophilin A; MYH11, smooth muscle myo-
sin heavy chain; MYOCD, myocardin; SMTN,
smoothelin; SRF, serum response factor; TA-
GLN, smooth muscle protein 22-.
C601CONTROLLED PHENOTYPIC MODULATION OF HUMAN VISCERAL SMCs
AJP-Cell Physiol • doi:10.1152/ajpcell.00167.2017 • www.ajpcell.org
Downloaded from journals.physiology.org/journal/ajpcell at Universiteit Maastricht (137.120.156.250) on October 29, 2020.
after PDGF-BB and TGF-1 stimulation, no differences in
SM-MHC protein levels were observed. On the other hand,
MYH11 mRNA levels were markedly induced by TGF-1
treatment, along with induction of ACTG2, TAGLN, SMTN,
SRF, and MYOCD (Fig. 5, B and C). Treatment with PDGF-BB
provoked significant reductions in ACTA2, CALD1, and SRF
levels, as well as smaller, nonsignificant reductions of ACTG2,
TAGLN, MYH11, and MYOCD. Overall, these data not only
indicate that visceral SMCs can be kept in a contractile phe-
notype by culturing them on BM matrix for a prolonged time,
but also show that their phenotype can still be modulated in a
controlled way toward both a more contractile and a more
synthetic state.
Validation of culture conditions for controlled phenotypic
modulation of visceral smooth muscle cells. To demonstrate
that the culture conditions defined above can also be applied to
study phenotypic modulation in other visceral SMCs, we
validated our culture system using an independent uterine
smooth muscle cell line (hTERT-HM). These highly prolifer-
ative, immortalized SMCs have been shown to retain smooth
muscle-specific markers (e.g., -SMA, h-caldesmon, and cal-
ponin) and display an elongated phenotype, potentially indi-
cating a more contractile phenotype compared with ULTR
cells (7). We first compared the morphology of confluent
hTERT-HM cells grown on either TC- or BM-coated surfaces
(Fig. 6A). SMCs cultured on TC-coated surfaces adopted the
typical rhomboid-shaped morphology after 6 days, indicative
of the synthetic phenotype. In accordance with previous results
obtained using ULTR cells, we observed a homogeneous
population of elongated spindle-shaped cells when
hTERT-HM SMCs were cultured on BM-coated surfaces,
consistent with modulation toward the contractile phenotype.
Next, we validated the changes in protein expression levels of
SMC-specific contractile markers upon culturing on TC-coated
versus BM-coated surfaces (Fig. 6B). Similar to what was
observed for ULTR SMCs, hTERT-HM cells cultured on
BM-coated surfaces showed a marked upregulation of SM-
MHC (2.1-fold, P 
 0.001), -SMA (4.2-fold, P 
 0.001), and
SM22 (2.3-fold, P 
 0.001) protein compared with
hTERT-HM cells cultured on TC-coated surfaces. Finally, we
investigated whether contractile hTERT-HM SMCs grown on
BM were responsive to PDGF-BB and TGF-1 to stimulate
phenotypic modulation. Although these cells only slightly
decreased gene and protein expression levels of SMC-specific
contractile markers after PDGF-BB treatment, significantly
increased levels of these markers were observed after stimula-
tion with TGF-1 (Fig. 6, C–E). Altogether, these results
corroborate the data obtained with the ULTR cells and dem-
onstrate that the culture conditions defined above can be
applied to study phenotypic modulation in other visceral SMC
lines.
DISCUSSION
The present study describes culture conditions that can be
applied to keep visceral SMCs in a highly contractile state
while still allowing phenotypic modulation toward either a
more contractile or synthetic phenotype in a controlled way.
This is the first study in which the phenotypic response of
visceral SMCs to combinations of microenvironmental factors,
including cell-cell interactions, cell-BM interactions, and se-
rum concentrations, was systematically investigated. Whereas
serum deprivation did not significantly affect the SMC pheno-
type, increasing cell-cell interactions and cell-BM interactions
greatly promoted the acquisition and maintenance of a contrac-
tile phenotype.
The vast majority of previous studies on visceral SMC
phenotypic modulation used primary cells, which have impor-
tant drawbacks since they have a limited life span and display
uncontrolled phenotypic modulation toward the synthetic phe-
notype during the initial stages of culturing (6, 38). Together
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Fig. 3. Effect of serum on contractile marker expression in visceral smooth
muscle cell (SMCs) grown on basement membrane (BM). Visceral SMCs
(ULTR cells) were cultured on a BM-coated growth surface. When cells
reached 90% confluency, growth medium was replaced by differentiation
medium containing reduced serum concentrations (10%, 2%, or 0% FBS) for
6 days. A: protein expression levels of smooth muscle myosin heavy chain
(SM-MHC), -smooth muscle actin (-SMA), and smooth muscle protein
22- (SM22) were determined by Western blot analysis. All samples from
each independent experiment were derived at the same time and processed in
parallel (SM-MHC, n  6; -SMA and SM22, n  9). B: mRNA expression
levels of ACTA2, ACTG2, TAGLN SMTN, CALD1, and MYH11 were deter-
mined and are expressed as relative expression with day 0 samples set at 1.
Data were normalized to CYPA and B2M reference genes. Results from each
time point were obtained from two (CALD1, MYH11, n  6) or three (ACTA2,
ACTG2, TAGLN, and SMTN; n  9) independent experiments and are
presented as mean 	 SE (Kruskal-Wallis test followed by Dunn’s post hoc
testing with Bonferroni correction, *P 
 0.05). ACTA2, -smooth muscle
actin; ACTG2, -smooth muscle actin; B2M, -2-microglobulin; CALD1,
caldesmon; CYPA, cyclophilin A; MYH11, smooth muscle myosin heavy
chain; SMTN, smoothelin; TAGLN, smooth muscle protein 22-.
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with differences in the (epi)genetic background of the donor,
this greatly hampers reproducibility of studies. Our use of
established immortalized SMC lines ensures a consistent sup-
ply of cells with similar properties while also reducing practi-
cal logistic issues associated with isolating cells from tissue.
Vascular and visceral SMCs have been shown to display a
substantially different response to changes in microenviron-
mental stimuli (11, 12, 27). In addition, they express different
actin isoforms (39). Whereas -SMA is the classical marker of
early vascular SMC differentiation (25), -SMA is the domi-
nant actin isoform in visceral SMCs (esophagus, stomach,
intestine, bladder, and uterus) (1). Although we observed an
increased -SMA expression in confluent visceral SMCs
grown on a regular tissue culture-treated growth surface,
-SMA responded particularly strongly to the addition of
basement membrane matrix and TGF-1. This may indicate
that the optimized culture conditions described here more
closely resemble the in vivo visceral SMC microenvironment,
which is associated with relatively higher -SMA expression.
-SMA and other SMC contractile genes like SM22, smooth-
elin, and caldesmon are transcriptionally regulated by SRF and
its muscle-restricted cofactor myocardin (10, 41). Disruption of
the SRF-myocardin complex in vascular SMCs results in an
overall decrease of contractile marker proteins (40). In line
with this, loss of myocardin causes profound defects in the
vasculature. Since the gastrointestinal and genitourinary tracts
are also affected in myocardin knockouts, myocardin is
thought to be required in both vascular and visceral SMCs (17).
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Fig. 4. Controlled modulation of morpholog-
ical and structural characteristics of visceral
smooth muscle cell (SMCs). Visceral SMCs
(ULTR cells) were grown on either tissue
culture (TC)-coated or basement membrane
(BM)-coated surfaces. When cells reached
90% confluency, confluent cells were kept
for 6 days in culture medium containing either
10% or 2% FBS, respectively. A and B:
phase-contrast microphotographs (a, b, d, and
e, bar  200 m; c and f, bar  100 m) (A)
and double-immunofluorescence staining
(bar, 10 m) (B) showing -smooth muscle
actin (-SMA) and smooth muscle protein
22- (SM22) expression in visceral SMCs
cultured on TC-coated (a–c) and BM-coated
(d–f) surfaces. Nuclei are stained in blue by
DAPI.
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Our results confirm expression of SRF and myocardin in
uterine SMCs in vitro and show that their levels increase in
parallel with contractile SMC markers when confluent visceral
SMCs are cultured on BM matrix. Importantly, we observed
only low expression of SRF and myocardin in SMCs cultured
on tissue culture-treated plastic.
The basement membrane that surrounds SMCs in vivo
consists of laminin, collagen IV, heparin sulfate proteoglycan,
entactin, and various growth factors (i.e., fibroblast growth
factor, TGF-1, epidermal growth factor, etc.). When SMCs
are isolated from tissues, this extracellular environment is lost,
and contractile and cytoskeletal filaments are reorganized to
adapt to a two-dimensional culture environment, resulting in
the acquisition of a synthetic phenotype (35). However, rein-
troduction of basement membrane components like laminin
and collagen IV has been shown to promote the contractile
phenotype in vascular SMCs (14, 20, 35, 37). To mimic the in
vivo microenvironment associated with the contractile pheno-
type in culture, we used a growth factor-reduced basement
membrane matrix (Geltrex) that is purified from the Engel-
breth-Holm-Swarm tumor. The composition of this matrix is
similar to the basal lamina that surrounds SMCs in vivo (19).
Since we observed marked induction of all contractile markers
and their transcriptional regulators upon culturing human uter-
ine SMCs on a basement membrane-coated growth surface,
components of the basement membrane matrix appear to in-
duce a contractile phenotype in visceral SMCs as well. Fur-
thermore, the stiffness of the basement membrane-coated sur-
face is likely to be different from that of regular uncoated
surfaces used to culture cells, which also affects the SMC
phenotype. For example, SMCs are known to proliferate more
quickly on stiff compared with soft substrates, indicating a
synthetic phenotype (29). In line with this, we found that the
relatively soft surface provided by the basement membrane
coating was associated with a more contractile phenotype.
Withdrawal of FBS from the culture medium is a commonly
used method to initiate differentiation of many different cell
types, including vascular SMCs (18, 21, 43). For example,
Solodushko and colleagues (34) showed that confluent serum-
starved vascular SMCs respond to increased serum concentra-
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Fig. 5. Controlled modulation of the visceral
smooth muscle cell (SMC) phenotype by
PDGF-BB and transforming growth factor 1
(TGF-1). Visceral SMCs (ULTR cells) were cul-
tured for 6 days with 2% FBS to induce the expres-
sion of contractile SMC markers. After 6 days, cells
were incubated with either PDGF-BB (30 ng/ml) or
TGF-1 (5 ng/ml). A: protein expression levels of
smooth muscle myosin heavy chain (SM-MHC),
-smooth muscle actin (-SMA), and smooth mus-
cle protein 22- (SM22) were determined by
Western blot analysis after 48 h. B and C: mRNA
expression levels of contractile (ACTA2, ACTG2,
TAGLN, SMTN,CALD1, and MYH11) (B) and tran-
scriptional regulatory (SRF, MYOCD) (C) genes
were determined after 24 h. mRNA expression
levels are expressed as relative expression levels
with untreated samples set at 1. Data were normal-
ized to CYPA and B2M reference genes. Results
were obtained from two (CALD1 and MYH11; n 
6) or three (ACTA2, ACTG2, TAGLN, SMTN, SRF,
and MYOCD; n  9) independent experiments
(mean 	 SE, Kruskal-Wallis test followed by
Dunn’s post hoc testing with Bonferroni correction;
*P 
 0.05). ACTA2, -smooth muscle actin;
ACTG2, -smooth muscle actin; B2M, -2-
microglobulin; CALD1, caldesmon; CYPA, cyclo-
philin A; MYH11, smooth muscle myosin heavy
chain; MYOCD, myocardin; SMTN, smoothelin;
SRF, serum response factor; TAGLN, smooth mus-
cle protein 22-.
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tions with increased cell cycle progression and increased DNA
synthesis, indicating that serum factors overrule contact inhi-
bition in confluent vascular SMCs. Similar results were re-
ported by Kato and colleagues (18), who showed that high FBS
concentrations promoted cell cycle progression and increased
total protein and collagen synthesis rates in comparison to low
serum conditions in postconfluent rat aortic SMCs. Along this
line, we expected that serum deprivation would promote a shift
toward the contractile phenotype. However, reducing serum
concentrations had only minimal effects on the expression of
contractile markers in visceral SMCs cultured on basement
membrane matrix. This may be explained by the fact that
basement membrane matrix proteins inhibit growth factor-
induced proliferation and, therefore, inhibit the shift toward the
synthetic phenotype (9, 16).
Previous studies have shown that cell-cell contact induces
growth arrest of vascular SMCs, which subsequently results in
the induction of smooth muscle specific contractile proteins (4,
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Fig. 6. Validation of culture conditions for
controlled phenotypic modulation of visceral
smooth muscle cells (SMCs) using telomer-
ase-immortalized human myometrial cells
(hTERT-HM). Human hTERT-HM SMCs
were grown on either tissue culture (TC)-
coated or basement membrane (BM)-coated
surfaces. When cells reached 90% conflu-
ency (day 0), confluent cells were kept for 6
days in culture medium containing either 10%
or 2% FBS, respectively. A: phase-contrast
microphotographs. Confluent SMCs grown
on TC-coated surfaces (left) and confluent
SMCs grown on BM-coated surfaces (right)
at day 6. B: protein expression levels of
smooth muscle myosin heavy chain (SM-
MHC), -smooth muscle actin (-SMA), and
smooth muscle protein 22- (SM22) (B)
expressed by hTERT-HM SMCs cultured on
either TC-coated surfaces (day 0) or BM-coated
surfaces (day 6). Protein expression levels were
determined by Western blot analysis. All sam-
ples from each independent experiment (n  3,
each with biological triplicates) were derived at
the same time and processed in parallel. Results
are presented as mean 	 SE (Mann-Whitney
U-test, *P 
 0.05). C and D: mRNA expression
levels of contractile (ACTA2, ACTG2, TAGLN,
SMTN, and CALD1) (C) and transcriptional reg-
ulatory (SRF, MYOCD) (D) markers were de-
termined in hTERT-HM SMCs treated with
PDGF-BB and TGF-1 (24 h). Results are ex-
pressed as relative expression with untreated
samples set at 1. Data were normalized to CYPA
and B2M reference genes and are presented as
mean 	 SE. E: protein expression levels of SM-
MHC, -SMA, and SM22 were determined
by Western blot analysis after hTERT-HM were
treated for 48 h with either PDGF-BB or TGF-
1. (Kruskal-Wallis test followed by Dunn’s
post hoc testing with Bonferroni correction;
*P 
 0.05). ACTA2, -smooth muscle actin;
ACTG2, -smooth muscle actin; B2M, -2-mi-
croglobulin; CALD1, caldesmon; CYPA, cyclo-
philin A; MYOCD, myocardin; SMTN, smooth-
elin; SRF, serum response factor; TAGLN,
smooth muscle protein 22-.
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18, 26). Even in the presence of 10% FBS, density-induced
growth arrest has been shown to be associated with elevated
-SMA expression in vascular SMCs (18, 26). In contrast to
this, we only observed a minimally increased expression of
contractile protein markers and their transcriptional regulators
in visceral SMCs kept confluent for 6 days. This indicates that
visceral SMCs are less responsive to the increases in cell-cell
interactions in the postconfluent state compared with vascular
SMCs.
A limitation of our culture model is the absence of non-
muscle cells that regulate the contractile functionality of
SMCs, such as neuronal cells and the interstitial cells of Cajal.
Furthermore, it should be noted that we cannot distinguish
between cell hypertrophy and increased cell proliferation as a
cause of smooth muscle marker protein differences between
the different culture conditions. In addition, immortalized cell
lines can acquire different characteristics compared with nor-
mal cells due to activation of different gene expression pro-
grams. Nevertheless, SMC plasticity remained intact in our
model since contractile marker expression could be both in-
duced and repressed.
In conclusion, we developed a novel visceral SMC culture
system in which confluent visceral SMCs can be kept in a
contractile phenotype by culturing on a BM coating under low
serum conditions. This contractile phenotype can be further
modulated toward a more contractile or a more synthetic state
by TGF-1 or PDGF-BB stimulation. As such, this SMC
culture system represents a highly suitable model to study
phenotypic modulation of visceral SMCs in health and disease.
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